In today's interview, we have the pleasure of speaking with Ivan Kairatov, a biopharma expert renowned for his expertise in technology and innovation within the industry. With extensive experience in research and development, Ivan provides invaluable insights into the current challenges and
In recent years, the aging global population has brought significant attention to age-related health issues, especially sarcopenia—a condition marked by the loss of muscle mass and function. As traditional approaches such as exercise and nutrition struggle to counteract the cellular dysfunctions
Ivan Kairatov is a renowned expert in the biopharma industry, particularly in the realms of technology and innovation. His expertise in research and development has helped shape advancements in targeted cancer therapies. We discuss the recent FDA approval of the tablet formulation of Brukinsa, a
Multiple myeloma remains a formidable challenge in oncology, known for its relentless cycle of relapse and treatment resistance. This blood cancer, which originates in plasma cells within the bone marrow, continues to affect patients profoundly, with around 6,240 individuals diagnosed annually in
Heart failure is emerging as a critical battlefield in modern medicine, with a striking gap in specialist care endangering patient survival. While cancer patients routinely receive oncological consultations, heart failure patients often lack consistent access to cardiologists. Research by French
Ivan Kairatov, a renowned figure in biopharmaceutical research, has been at the forefront of integrating technological innovations within the field. His recent study delves into the critical role of timely statin therapy in managing cardiovascular risks among diabetes patients. Today, we explore
